Teva CEO on Drug Pricing, Generics, Supply Shortages
Teva Pharmaceuticals CEO Richard Francis reflects on company performance in 2024, drug pricing, getting more drugs to market, supply shortages of the drug Adderall, and selling GLP-1 drugs. He speaks to "Bloomberg Open Interest" from the JPMorgan Healthcare Conference.
Duvakitug And Teva's Growth: A Game Changer In Pharma
On December 17, Teva Pharmaceutical Industries Limited reported that duvakitug had shown stunning results in a phase 2b study for the treatment of Crohn's disease and ulcerative colitis. However, a month and a half before this news, the Israeli pharmaceutical company pleased investors by once again beating analysts' expectations by a wide margin. So, Uzedy's sales amounted to $35 million in the third quarter of 2024, increasing more than 16 times year-on-year.
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).
Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength?
Teva Pharmaceutical Industries (TEVA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
TEVA stock soars 26%: What's going on with Teva Pharmaceuticals?
Teva Pharmaceuticals (NASDAQ: TEVA) and its partner Sanofi (NASDAQ: SNY) have announced groundbreaking results from clinical trials of their drug, duvakitug, for ulcerative colitis and Crohn's disease, two of the most prevalent forms of inflammatory bowel disease (IBD). The announcement, which sent Teva's stock soaring by 26.4% to $20.88 and Sanofi's up 6.7% to $48.
Overlooked Stock: TEVA
Teva Pharmaceutical (TEVA) closed at its highest stock price of the year after it and Sanofi (SNY) say their IBD treatment had higher remission in trial. George Tsilis looks at how the development can be the first step in a turnaround for the company.
Teva price target raised to $25 from $23 at BofA
BofA raised the firm's price target on Teva to $25 from $23 and keeps a Buy rating on the shares. The price target increase reflects the strong Phase 2 update for duvakitug as a treatment for inflammatory bowel disorders, the analyst tells investors in a research note. The firm now forecasts nominal peak sales of roughly $2B, with Teva booking half the profits, based on the strength of the data and the emerging product profile.
Can Teva Return To All-Time Highs?
Teva Pharmaceutical stock has rebounded from lows, driven by debt reduction, halted price deflation in generics, and new product launches, making it a strong buy. Teva's innovative branded drugs and biosimilar pipeline, including AUSTEDO and upcoming biosimilars like PROLIA and RANIVISIO, offer substantial growth opportunities. Teva's business has followed a boom and bust cycle. Substantial biologic patent expirations in the coming years point to another boom.
Pharma firm Teva to divest its business venture in Japan
Teva Pharmaceutical Industries said on Thursday it will transfer ownership of its business venture that sold generics in Japan to JKI.
Teva Pharmaceutical Industries Limited (TEVA) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) 7th Annual Evercore ISI HealthCONx Healthcare Conference Call December 5, 2024 8:20 AM ET Company Participants Richard Francis - President and Chief Executive Officer Eric Hughes - Executive Vice President, Global R&D and Chief Medical Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Thank you, guys for being here. Super excited to have Teva management.
TEVA Stock Down 10% in a Month: Should You Buy the Dip?
Teva's reasonable valuation, an improving pipeline, and sales and profit growth potential are good enough reasons for those who own the stock to stay invested.
2 Generic Drug Stocks Ready to Surge in 2025
Generic and biosimilar drugs are often preferred over the brand name version due to their cheaper prices. Generics are exact duplicates of the branded counterparts, while biosimilars are "similar" and often require clinical trials.
